



Dr. Madden obtained his BSc. and Ph.D. in Biochemistry from the University of London, U.K. He has held several senior academic and industry positions. He played an instrumental role in the development of several approved drugs including Myocet®, Ablecet® and Marqibo. Dr. Madden founded Acuitas Therapeutics in 2009 and has guided the company to a leadership position in the application of lipid nanoparticle (LNP) technology for delivery of nucleic acid therapeutics, in particular messenger RNA therapeutics. Dr. Madden has over 60 publications in peer-reviewed journals relating to LNP technology and development of pharmaceutical products, including recent publications in Nature.